China's Fosun International Increases Stake In Simcere For Ninth Time
This article was originally published in PharmAsia News
Executive Summary
Fosun International, a Hong Kong unit of China's Fosun Pharma, has bought shares of New York Stock Exchange-listed Chinese drug maker Simcere for the ninth time since Aug. 8